Nathan Diers promoted to Vice President of Product Development

Rallying around Start-Ups struggling in COVID-19 pandemic. MMG - Mike Margiotta Group is a privately owned Consulting Group launching in response to the fallout from the spread of coronavirus infections.

A new study uses large-scale genetic approach to uncover human genes controlling HIV infection.

$450,000 Award from Chan Zuckerberg Initiative is Part of Rare As One Project Investing $13.5 Million to Drive Progress Against Rare Diseases

With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer's disease.

New study shows potentiating a subset of NMDA receptors may be beneficial in Alzheimer's disease and Dravet syndrome.

The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies

This is an IRB-approved clinical trial aimed at reversing aging in humans. It is being conducted as a pay-to-play trial with a $1 million price tag to enroll.

Machine, Meet Stem Cells

New study shows how patterns in brain activity can be an early predictor of Alzheimer's symptoms

The research will focus on nanotechnology-based CBD products for the treatment of psoriasis and other diseases

NIH award supports collaborative work to discover the connection between neurovascular dysfunction and cognitive decline in Alzheimer's disease.

Cambridge Isotope Laboratories, Inc. (CIL) board of directors appointed Cliff Caldwell as its new chief executive officer (CEO), as Joel Bradley, founder and CEO, stepped down from his position after 38 years.

Gladstone researchers Warner C. Greene and Eytan Herzig collaborated with Xyphos Biosciences, Inc., to develop a novel immunotherapy for HIV.

The Virtual Center for Velo-Cardio-Facial Syndrome collaborates with the Center for Precision Neuropsychiatry based in the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons

The European clinical laboratory services market surpassed USD 49 billion in 2018 and is set to achieve a significant CAGR up to 2025, driven by well-equipped healthcare infrastructure.

The biotech company MedaRed, Inc. is founded on groundbreaking basic research from Gladstone Institutes, UC San Francisco, and UC San Diego